DBV re­struc­tur­ing claims 200 jobs as it beats out a path to­ward peanut patch OK

Reg­u­la­to­ry trou­bles around its peanut al­ler­gy treat­ment have hurt DBV Tech­nolo­gies bad.

It be­came even clear­er Thurs­day morn­ing as the French biotech dis­closed the scope of a glob­al re­struc­tur­ing it an­nounced back in June. More than 200 jobs are be­ing cut, leav­ing a team of 90 to car­ry on with the hard task of scor­ing ap­proval for its Vi­askin Peanut patch.

With a for­mal go-ahead from au­thor­i­ties in France, CEO Daniel Tassé ex­pects the mea­sures to re­duce av­er­age month­ly cash burn by up to half, there­by keep­ing the com­pa­ny afloat un­til late 2022.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA